NEW YORK (GenomeWeb News) - German-based TheraCode, a wholly owned subsidiary of biotech firm BioNTech, has announced its intentions to buy JPT Peptide Technologies, also based in Germany, for €5 million ($6.8 million) in an all-cash deal.

JPT had been a wholly owned subsidiary of Jerini, which sold the company as part of its strategy to divest non-strategic businesses and focus on its core business, the commercialization of the drug icatibant (Firazyr) for the treatment of hereditary angioedema.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.